Saturday, March 5, 2022

Pfizer and Moderna set to make $51 BILLION in COVID-19 vaccine sales this year

Pfizer and Moderna, manufacturers of the two most popular used vaccines in the United States and much of the rest of the world, are expecting to bring in $51 billion in vaccine sales this year, according to earnings statements published by the companies.

Moderna and Pfizer, which partners with the German company BioNTech for the development and manufacturing of Covid vaccines and splits profits with, both have a Omicron-specific vaccine expected to become available in the coming weeks.

The WHO has called for greater vaccine equity across the world, as many developing nations, and specifically those in Africa, have had trouble getting the vaccine to their population.

While in countries like America, the vaccine is widely available to everyone who wants it - and millions of doses are even trashed due to lack of demand - in Africa only 19 percent of residents have received at least one shot of a COVID-19 vaccine and 12 percent are fully vaccinated.

Pfizer CEO Albert Bourla and President Joe Biden have both previous stated that vaccine uptake remains limited in Africa because of vaccine hesitancy in the countries.

The U.S. has pledged to donate upwards of 1.1 billion COVID-19 vaccine doses to developing nations, but advocacy groups like Doctors Without Borders have said that these types of donations are not enough, and that developing nations need to be allowed to develop their own versions of the shots.

'The U.S. must help dramatically scale up mRNA vaccine production globally-like through the World Health Organization's COVID-19 mRNA Vaccine Technology Transfer Hub in South Africa-by demanding that pharmaceutical corporations share the technology and know-how for mRNA vaccines so that many more manufacturers globally can produce these lifesaving vaccines,' Dr Carrie Teicher, director of programs for Doctors Without Borders, said in a statement.

https://www.dailymail.co.uk/health/article-10579091/Pfizer-Moderna-set-make-51-BILLION-COVID-19-vaccine-sales-year.html 

No comments: